Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT05014815

Public ClinicalTrials.gov record NCT05014815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.

Study identification

NCT ID: NCT05014815
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: BeiGene; Industry
Enrollment: 272 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 16, 2021 (Actual)
Primary completion: Sep 4, 2024 (Actual)
Completion: Sep 4, 2024 (Actual)
Last update posted: Sep 16, 2025

2021 – 2024

United States locations

U.S. sites: 11
U.S. states: 8
U.S. cities: 11

Facility	City	State	ZIP	Site status
Valkyrie Clinical Trials	Los Angeles	California	90067-2011	—
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242-1009	—
Comprehensive Cancer Center of Nevada	Las Vegas	Nevada	89169-3321	—
Rj Zuckerberg Cancer Center	New Hyde Park	New York	11042-1118	—
North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists (New York)	New York	New York	10028-0517	—
North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists	Port Jefferson Station	New York	11776-8066	—
Ny Cancer and Blood Specialists	The Bronx	New York	10469-5930	—
Xcancerdayton Physician Network	Dayton	Ohio	45409-1328	—
Tennessee Cancer Specialist	Knoxville	Tennessee	37909-1327	—
Texas Oncology Tyler Longview	Austin	Texas	78705-1163	—
Cancer Care Northwest	Spokane Valley	Washington	99216-1020	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05014815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 16, 2025 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05014815 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →